View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 16, 2022

Medtronic concludes Intersect ENT acquisition

The deal adds Intersect ENT's PROPEL and SINUVA sinus implant product lines and technology to Medtronic's portfolio.

Medtronic has completed the acquisition of health care equipment company Intersect ENT, further strengthening its ear, nose and throat (ENT) portfolio.

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

The deal was first announced last August, when Medtronic agreed to acquire all outstanding Intersect ENT shares for nearly $1.1bn in cash.

According to a company statement, the acquisition adds Intersect ENT’s PROPEL and SINUVA sinus implant product lines and technology to Medtronic’s portfolio.

Medtronic will also gain related intellectual property and a facility in Menlo Park, California, US.

As part of the deal, Intersect ENT’s workforce will also migrate to the new ownership.

However, former Intersect ENT brand Fiagon and its products, the Cube navigation system and VenSure balloon sinus dilation system, were not included in the deal.

Intersect ENT president and CEO Thomas West said: “We believe the market leadership and global footprint of Medtronic, coupled with enterprise resources to fuel pipeline innovation and commercialisation, will advance our reach to customers and patients more quickly and serve our shared vision of improving patient access, outcomes, and satisfaction for millions of people around the world who suffer from ENT diseases.”

Separately, Medtronic announced that its Onyx Frontier drug-eluting stent (DES) has secured US Food and Drug Administration (FDA) approval.

The Onyx Frontier DES is designed to treat coronary artery disease (CAD). The latest in the Resolute DES family, the stent will help cardiologists address complex coronary cases.

In March, Medtronic announced the first implant of its investigational implantable tibial neuromodulation (TNM) device in a patient for its TITAN 2 pivotal study.

Related Companies

Free Report
img

Find the right pricing strategy for your medical device

How do your competitors set prices in different markets? Will reducing your prices win market share from your main competitors? Do you need to position products differently for different markets? To find out, use our Global Brand Pricing tool to achieve optimal pricing for your devices. Detect price changes, understand competitor market positioning, and plan new product launches, by accessing this tool today. It features:
  • A proprietary algorithm that leverages numerous pricing sources, with an emphasis on real-world data
  • Estimates of the likely spread of selling prices per brand and manufacturer, as well as 3-year forecasts for prices
  • Medical device pricing data that can be tracked by market, company, and brand
  • Additional categories that can be built on a custom basis
Use our tool to access competitor pricing strategies across multiple geographies, and various dynamic case studies from the likes of Germany and China, to benchmark yourself against your competitors and future proof your pricing strategies.
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network